Bayer Regeneron Eye Drug Meets Study Goal
By wchung | 24 Mar, 2026
Regeneron Pharmaceuticals Inc. and Bayer HealthCare AG said Thursday their developing VEGF Trap-Eye drug met key vision improvement goals in a midstage study.
The drug is aimed at improving vision in patients with diabetic macular edema. The condition is a disease of the retina that affects individuals with diabetes and can lead to blindness.
The study, which took place over 24 weeks, compared VEGF Trap-Eye with laser therapy.
The companies also said VEGF Trap-Eye was well tolerated, and there were no drug-related serious adverse events.
Shares of Regeneron, which is based in Tarrytown, N.Y., closed at $30.46 Wednesday. Bayer HealthCare AG is based in Germany.
2/18/2010 8:18 AM NEW YORK (AP)
Articles
- World's 25 Most Polluted Cities All in India, Pakistan and China
- Flight Cancellation Spread Across Globe on Mideast Hub Closures
- S. Korea Calls for Nationwide Campaign to Conserve Fuel
- Vietnam Airlines Cancels Flights Due to Jet Fuel Shortage
- Alibaba's 5-nm Agentic AI Chip Unveiled As World's Most Powerful RISC-VCPU
- What's Ro Khanna's Angle with Thomas Massie?
- Top 5 Date Turn-Offs for Women and Men
- Demand Builds for Affordable Chinese EVs Among American Carbuyers
- OpenAI Bumps Up Minimum Return to 17.5% in Competition with Anthropic for Private Equity
- China's Open-Source AI Dominates Global Downloads, Threatens US Leadership